The company says it has managed to stop cancer cells growing in a lab
A University of Bath spin-out developing a novel way to treat cancer has secured £572,000 in its latest fundraise. Revolver Therapeutics said the funding would be used to support its scientific work focusing on therapeutics for colorectal cancer, including creating a pipeline of new treatments.
The round was led by QantX, with follow-on investment from the UK Innovation & Science Seed Fund (UKI2S) managed by Future Planet Capital, as well as from the University of Bath.
Jody Mason, chief scientific officer of Revolver Therapeutics and professor of biochemistry in the University of Bath’s Department of Life Sciences, said the funding was “a huge vote of confidence” in the team and the science being built in Bath.
“Backing like this is exactly what a spin-out needs to take bold science from the lab and turn it into something that could genuinely help patients,” he said.
“We’ve already shown we can stop tumour cells growing in the lab while cracking the challenge of getting our molecules inside cells – a hurdle that has held this field back for years.
“This investment lets us build on that progress, starting with colorectal cancer, and move closer to new treatments for the people who need them most. We’re hugely grateful to our investors for believing in what we’re trying to achieve – for colorectal cancer and beyond.”
Richard Haycock, co-founder and chief executive of QantX, said Revolver could “open the door” to a whole new way of treating cancer and other hard-to-tackle diseases.
“That’s exactly the kind of hard science QantX exists to back,” he said. “They’re a standout example of world-class innovation coming out of the South West of England, taking on one of the toughest challenges in cancer research.
Oliver Sexton, investment director at UKI2S, managed by Future Planet Capital, added: “Revolver continues to pioneer an exciting new approach to cancer treatment by targeting transcription factors – proteins that have been tough to tackle in cancer research until now.”
Revolver Therapeutics was spun out of the University of Bath with the support of the Technology Transfer team in Research and Innovation Services (RIS), which helped translate professor Mason’s pioneering research into a commercial venture and continues to back the company as it grows.
Jennifer Rogers, technology transfer team, RIS at the University of Bath, said: “It’s a wonderful example of how university research can grow into a company with the potential to change patients’ lives, and we’re proud to have supported the team on this journey from the very beginning.”






You must be logged in to post a comment Login